Dermata Therapeutics Inc (DRMA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Dermata Therapeutics Inc stock (DRMA) is currently trading at $1.55. Dermata Therapeutics Inc PE ratio is 0.10. Analyst consensus price target for DRMA is $10.00. WallStSmart rates DRMA as Sell.
- DRMA PE ratio analysis and historical PE chart
- DRMA PS ratio (Price-to-Sales) history and trend
- DRMA intrinsic value — DCF, Graham Number, EPV models
- DRMA stock price prediction 2025 2026 2027 2028 2029 2030
- DRMA fair value vs current price
- DRMA insider transactions and insider buying
- Is DRMA undervalued or overvalued?
- Dermata Therapeutics Inc financial analysis — revenue, earnings, cash flow
- DRMA Piotroski F-Score and Altman Z-Score
- DRMA analyst price target and Smart Rating
Dermata Therapeutics Inc
📊 No data available
Try selecting a different time range
DRMA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Dermata Therapeutics Inc (DRMA)
DRMA trades at a significant discount to its Graham intrinsic value of $103.63, offering a 99% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Dermata Therapeutics Inc (DRMA) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Dermata Therapeutics Inc (DRMA) Key Strengths (1)
Trading at 1.04x book value, attractively priced
Supporting Valuation Data
Dermata Therapeutics Inc (DRMA) Areas to Watch (3)
Company is destroying shareholder value
Very low institutional interest at 7.58%
Micro-cap company with very limited liquidity and high volatility
Dermata Therapeutics Inc (DRMA) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 8.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.04) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Institutional Own., Market Cap. Profitability pressure is visible in Return on Equity at -203.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -203.40% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DRMA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Dermata Therapeutics Inc (DRMA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Dermata Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Dermata Therapeutics Inc.
Bottom Line
Dermata Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(12 last 3 months)
| Insider | Type | Shares |
|---|---|---|
BEDOYA-TORO, MUNERA MARIA E SVP, Regulatory Affairs | Buy | +1,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:23:03 AM
About Dermata Therapeutics Inc(DRMA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for dermatological conditions, particularly through its lead asset, DMT310, which utilizes a novel delivery system to improve treatment efficacy for acne and other skin disorders. The company is committed to addressing significant unmet needs in the dermatology market with a strategically designed pipeline aimed at advancing skin health. As Dermata navigates its clinical trials, it leverages proprietary technology to create effective, safe, and user-friendly therapeutic solutions that position it for leadership in the dermatological arena. With a strong emphasis on patient outcomes, Dermata is poised to make a meaningful impact in the treatment of skin-related issues.